Drug intelligence / Profile preview

Jango-Org-C1

Development stage: Preclinical
Lead developer: JangoBio
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Transplantation

Overview

Jango-Org-C1 is an organoid-based cell therapy developed by JangoBio using their proprietary Organoid ImmunoAdapt platform. It is specifically designed for veterinary applications, targeting hypogonadism and the promotion of healthy aging in canine populations. The therapy utilizes organoid technology to potentially restore hormonal balance and immune function, addressing age-related decline. It is currently being developed under JangoBio's JangoPet subsidiary and is in the preclinical stage of development.

Other names: Organoid ImmunoAdapt

Beyond the preview

Go deeper on Jango-Org-C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jango-Org-C1.

Explore the full profile